VDR and deubiquitination control neuronal oxidative stress and microglial inflammation in Parkinson’s disease

[1]  Sang-Soo Park,et al.  Deubiquitinating enzyme YOD1 deubiquitinates and destabilizes α-synuclein. , 2023, Biochemical and biophysical research communications.

[2]  Eliona Tsefou,et al.  Targeting Deubiquitinating Enzymes (DUBs) That Regulate Mitophagy via Direct or Indirect Interaction with Parkin , 2022, International journal of molecular sciences.

[3]  F. Pérez-Severiano,et al.  Oxidative Stress and Mitochondrial Complex I Dysfunction Correlate with Neurodegeneration in an α-Synucleinopathy Animal Model , 2022, International journal of molecular sciences.

[4]  D. Klenerman,et al.  Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity , 2022, Nature Neuroscience.

[5]  A. Higashitani,et al.  Mitochonic Acid 5 Improves Duchenne Muscular Dystrophy and Parkinson’s Disease Model of Caenorhabditis elegans , 2022, International journal of molecular sciences.

[6]  B. Tang,et al.  Assessing the Effects of Vitamin D on Neural Network Function in Patients With Parkinson’s Disease by Measuring the Fraction Amplitude of Low-Frequency Fluctuation , 2021, Frontiers in Aging Neuroscience.

[7]  N. Xiong,et al.  Targeting Microglial α-Synuclein/TLRs/NF-kappaB/NLRP3 Inflammasome Axis in Parkinson’s Disease , 2021, Frontiers in Immunology.

[8]  Lu Shan,et al.  Antioxidant capacity of flavonoids from Folium Artemisiae Argyi and the molecular mechanism in Caenorhabditis elegans. , 2021, Journal of ethnopharmacology.

[9]  J. Amaral,et al.  Oxidative stress and regulated cell death in Parkinson’s disease , 2021, Ageing Research Reviews.

[10]  O. Hobert,et al.  DAF-16/FoxO and DAF-12/VDR control cellular plasticity both cell-autonomously and via interorgan signaling , 2020, bioRxiv.

[11]  Jie Du,et al.  Vitamin D/VDR attenuate cisplatin-induced AKI by down-regulating NLRP3/Caspase-1/GSDMD pyroptosis pathway , 2020, The Journal of Steroid Biochemistry and Molecular Biology.

[12]  O. Ilkayeva,et al.  Multiple metabolic changes mediate the response of Caenorhabditis elegans to the complex I inhibitor rotenone. , 2020, Toxicology.

[13]  Xi-xiu Xie,et al.  The Role of α-Synuclein Oligomers in Parkinson’s Disease , 2020, International journal of molecular sciences.

[14]  C. Murphy,et al.  Metformin rescues Parkinson’s disease phenotypes caused by hyperactive mitochondria , 2020, Proceedings of the National Academy of Sciences.

[15]  Xiaojun Wu,et al.  Pepper component 7-ethoxy-4-methylcoumarin, a novel dopamine D2 receptor agonist, ameliorates experimental Parkinson's disease in mice and Caenorhabditis elegans. , 2020, Pharmacological research.

[16]  X. Tan,et al.  The relationships of vitamin D, vitamin D receptor gene polymorphisms, and vitamin D supplementation with Parkinson’s disease , 2020, Translational Neurodegeneration.

[17]  A. Nazir,et al.  Human insulin modulates α-synuclein aggregation via DAF-2/DAF-16 signalling pathway by antagonising DAF-2 receptor in C. elegans model of Parkinson’s disease , 2020, Oncotarget.

[18]  F. Fu,et al.  Neuroprotective effects of Danshensu on rotenone-induced Parkinson’s disease models in vitro and in vivo , 2020, BMC Complementary Medicine and Therapies.

[19]  B. Braeckman,et al.  DAF-16/FoxO in Caenorhabditis elegans and Its Role in Metabolic Remodeling , 2020, Cells.

[20]  Xiong Wang,et al.  Vitamin D receptor rs2228570 polymorphism and Parkinson’s disease risk in a Chinese population , 2019, Neuroscience Letters.

[21]  Binghao Wang,et al.  Vitamin D Receptor Inhibits NLRP3 Activation by Impeding Its BRCC3-Mediated Deubiquitination , 2019, Front. Immunol..

[22]  A. Schapira,et al.  Parkinson disease , 2019, European journal of neurology.

[23]  P. Maciel,et al.  GST-4-Dependent Suppression of Neurodegeneration in C. elegans Models of Parkinson’s and Machado-Joseph Disease by Rapeseed Pomace Extract Supplementation , 2019, Front. Neurosci..

[24]  S. Maji,et al.  α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis. , 2019, Biochimica et biophysica acta. Proteins and proteomics.

[25]  Yun-il Lee,et al.  The Impairments of α-Synuclein and Mechanistic Target of Rapamycin in Rotenone-Induced SH-SY5Y Cells and Mice Model of Parkinson’s Disease , 2019, Front. Neurosci..

[26]  D. Komander,et al.  Breaking the chains: deubiquitylating enzyme specificity begets function , 2019, Nature Reviews Molecular Cell Biology.

[27]  J. Repa,et al.  1,25-Dihydroxyvitamin D3 enhances glucose-stimulated insulin secretion in mouse and human islets: a role for transcriptional regulation of voltage-gated calcium channels by the vitamin D receptor , 2019, The Journal of Steroid Biochemistry and Molecular Biology.

[28]  J. Quinn,et al.  A randomized, controlled pilot study of the effects of vitamin D supplementation on balance in Parkinson's disease: Does age matter? , 2018, PloS one.

[29]  Salvador Ventura,et al.  Small molecule inhibits α-synuclein aggregation, disrupts amyloid fibrils, and prevents degeneration of dopaminergic neurons , 2018, Proceedings of the National Academy of Sciences.

[30]  Craig D. Hughes,et al.  Picomolar concentrations of oligomeric alpha-synuclein sensitizes TLR4 to play an initiating role in Parkinson’s disease pathogenesis , 2018, Acta Neuropathologica.

[31]  Liguo Wang,et al.  DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4. , 2018, Molecular cell.

[32]  Ravinder J. Singh,et al.  Development of Vitamin D Toxicity from Overcorrection of Vitamin D Deficiency: A Review of Case Reports , 2018, Nutrients.

[33]  A. Breier,et al.  Detection of the Mitochondrial Membrane Potential by the Cationic Dye JC-1 in L1210 Cells with Massive Overexpression of the Plasma Membrane ABCB1 Drug Transporter , 2018, International journal of molecular sciences.

[34]  Vladyslav Povoroznyuk,et al.  Vitamin D supplementation guidelines , 2018, The Journal of Steroid Biochemistry and Molecular Biology.

[35]  S. Christakos,et al.  Biology and Mechanisms of Action of the Vitamin D Hormone. , 2017, Endocrinology and metabolism clinics of North America.

[36]  I. Zerr,et al.  α-synuclein interacts with PrPC to induce cognitive impairment through mGluR5 and NMDAR2B , 2017, Nature Neuroscience.

[37]  A. Mesecar,et al.  Steady-state kinetic studies reveal that the anti-cancer target Ubiquitin-Specific Protease 17 (USP17) is a highly efficient deubiquitinating enzyme. , 2016, Archives of biochemistry and biophysics.

[38]  D. Eyles,et al.  Vitamin D signaling and the differentiation of developing dopamine systems , 2016, Neuroscience.

[39]  P. Liu,et al.  Vitamin D regulates tyrosine hydroxylase expression: N-cadherin a possible mediator , 2015, Neuroscience.

[40]  Jiang-Feng Wu,et al.  Relationship of Structure and Function of DNA-Binding Domain in Vitamin D Receptor , 2015, Molecules.

[41]  K. Roemer,et al.  MDM2 binds and inhibits vitamin D receptor , 2015, Cell cycle.

[42]  P. Klivényi,et al.  Association of vitamin D receptor gene polymorphisms and Parkinson's disease in Hungarians , 2013, Neuroscience Letters.

[43]  F. Horak,et al.  The relationship between balance control and vitamin D in Parkinson's disease—a pilot study , 2013, Movement disorders : official journal of the Movement Disorder Society.

[44]  M. Urashima,et al.  Randomized, double-blind, placebo-controlled trial of vitamin D supplementation in Parkinson disease. , 2013, The American journal of clinical nutrition.

[45]  R. Fricker,et al.  Calcitriol Imparts Neuroprotection In Vitro to Midbrain Dopaminergic Neurons by Upregulating GDNF Expression , 2013, PloS one.

[46]  M. Delong,et al.  High prevalence of hypovitaminosis D status in patients with early Parkinson disease. , 2011, Archives of neurology.

[47]  P. Knekt,et al.  Serum vitamin D and the risk of Parkinson disease. , 2010, Archives of neurology.

[48]  M. Delong,et al.  Prevalence of vitamin d insufficiency in patients with Parkinson disease and Alzheimer disease. , 2008, Archives of neurology.

[49]  J. McGrath,et al.  Distribution of the Vitamin D receptor and 1α-hydroxylase in human brain , 2005, Journal of Chemical Neuroanatomy.

[50]  W. Rausch,et al.  Rotenone: from modelling to implication in Parkinson's disease. , 2019, Folia neuropathologica.

[51]  P. Dhawan,et al.  Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects. , 2016, Physiological reviews.